October 2008
Although gemcitabine-based chemotherapy is standard in advanced pancreatic cancer, the role of adjuvant chemotherapy is still incompletely defined.
In an oral presentation, Jeffrey A. Zonder, MD, Division of Hematology-Oncology, Karmanos Cancer Center, Wayne State University School of Medicine,Detroit, Michigan, reported updated results of SWOG 0232, a study of lenalidomide (Revlimid) plus dexamethasone compared with dexamethasone alone in patients with newly diagnosed multiple myeloma (MM).
Advertisement
Advertisement
Trending on HCPLive
1
Omalizumab-Facilitated OIT Enables Maintenance Dosing in Food Allergy
2
VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes
3
After Sickle Cell Gene Therapy, What Comes Next?
4
Namilumab Fails to Meet Primary End Point in Pulmonary Sarcoidosis
5